Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. 2021

Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
Department of Microbiology, Guilan University of Medical Sciences, Rasht, Iran.

In the current study, niosome-encapsulated tobramycin based on Span 60 and Tween 60 was synthesized and its biological efficacies including anti-bacterial, anti-efflux, and anti-biofilm activities were investigated against multidrug resistant (MDR) clinical strains of Pseudomonas aeruginosa. The niosomal formulations were characterized using scanning electron microscopy, transmission electron microscopy, and dynamic light scattering measurement. The encapsulation efficiency was found to be 69.54% ±; 0.67. The prepared niosomal formulations had a high storage stability to 60 days with small changes in size and drug entrapment, which indicates that it is a suitable candidate for pharmaceutical applications. The results of biological study showed the anti-bacterial activity via reduction of antibiotic resistance, enhanced anti-efflux and anti-biofilm activities by more folds in comparison to free tobramycin. In addition, niosome encapsulated tobramycin down-regulated the MexAB-OprM efflux genes, pslA and pelA biofilm related genes in MDR P. aeruginosa strains. The anti-proliferative activity of formulation was evaluated against HEK293 cell lines, which exhibited negligible cytotoxicity against HEK293 cells. The finding of our study shows that encapsulation of tobramycin in niosome enhanced the antibacterial activity and reduced antibiotic resistance in MDR strains of P. aeruginosa comparing to free tobramycin and it can be considered as a favorable drug delivery system.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
March 2021, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
September 2016, Molecules (Basel, Switzerland),
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
January 2019, International journal of nanomedicine,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
June 2021, Nanomaterials (Basel, Switzerland),
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
January 2020, PloS one,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
April 1974, La Nouvelle presse medicale,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
January 1980, Chemotherapy,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
January 2010, Archives of microbiology,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
July 2014, Antimicrobial agents and chemotherapy,
Mojtaba Hedayati Ch, and Arefeh Abolhassani Targhi, and Farzaneh Shamsi, and Fatemeh Heidari, and Zahra Salehi Moghadam, and Amir Mirzaie, and Reyhaneh Behdad, and Maryam Moghtaderi, and Iman Akbarzadeh
April 2022, Pharmaceutics,
Copied contents to your clipboard!